Endo International Wins Big on Preliminary Results
Endo International saw its shares make a solid gain to start off the week after the firm announced preliminary financial results for its third quarter.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Endo International PLC (NASDAQ: ENDP) saw its shares make a solid gain to start off the week after the firm announced preliminary financial results for its third quarter. Endo also affirmed its guidance for the 2017 full year. Third-quarter results are expected November 9.
For the third quarter, the company expects to see $0.85 in earnings per share (EPS) and revenue of roughly $785 million. The consensus estimates from Thomson Reuters are $0.66 in EPS on revenue of $784.88 million. The same period of last year reportedly had EPS of $1.01 and $884.34 in revenue.
As mentioned, Endo also affirmed its outlook for the 2017 full year. The company expects to see EPS in the range of $3.35 to $3.65 and revenues between $3.38 billion and $3.53 billion. Analysts are looking for EPS of $3.52 in EPS and $3.47 billion in revenue.
One of the big developments for Endo in this quarter is that the U.S. Patent and Trademark Office (PTO) issued to Endo’s Par Pharmaceutical operating company three new patents relating to Vasostrict (vasopressin injection, USP). All of these patents expire in January 2035.
[nativounit]
The company said that it plans to “aggressively defend and protect” its Vasostrict product franchise and intellectual property. This includes seeking to prevent the unapproved, non-sterile-to-sterile bulk compounding of vasopressin through a previously announced lawsuit filed by certain of its subsidiaries against the U.S. Food and Drug Administration (FDA) on October 26, 2017.
Currently Vasostrict remains the only FDA-approved vasopressin injection product indicated to increase blood pressure in adults with vasodilatory.
Shares of Endo traded up 10% at $6.47 on Monday, with a consensus analyst price target of $11.88 and a 52-week range of $5.77 to $19.93.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
